MHRA issues MS treatment risk update

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:
Contact MSUK

MHRA issues MS treatment risk update

Post by MSUK »

Image


Risk of progressive multifocal leukoencephalopathy (PML) is increased in patients receiving natalizumab (Tysabri) who have had previous immunosuppressant treatment.

The UK medicines regulator MHRA has issued a new warning over the MS treatment natalizumab (Tysabri).

There is already a risk of progressive multifocal leukoencephalopathy (PML) with the treatment, which was known when it was given a licence. PML is a potentially deadly - but rare - progressive, and demyelinating brain disease.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
Top
User avatar
HarryZ
Family Elder
Posts: 2572
Joined: Tue May 25, 2004 2:00 pm
Location: London, ON, Canada
Contact:
Contact HarryZ

Re: MHRA issues MS treatment risk update

Post by HarryZ »

squiffy2 wrote:Image


Risk of progressive multifocal leukoencephalopathy (PML) is increased in patients receiving natalizumab (Tysabri) who have had previous immunosuppressant treatment.
I"m surprised that they are just now starting to advise Tysabri patients of this increased risk. It is a well known fact that previous users of immunosuppressant drugs are in a higher risk category for PML. Makes you wonder.

Harry
Top
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Tysabri (Antegren, Natalizumab)”